In clinical research, the monitoring of protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) antiretroviral drugs is of significant interest due to the importance of assessing inter-individual and intra-individual metabolism variability. To be of practical use, it is essential that the analytical method used to monitor these drugs is fast and easy to perform, with minimal sample preparation, and without compromising precision and accuracy.
Compared with other methods, liquid chromatography (LC) in combination with tandem mass spectrometry (MS/MS) has the potential for simultaneous determination of antiretroviral drugs with greater specificity, lower detection limits and a broader dynamic range. Several approaches have been proposed for a fast and stable LCMS/ MS platform for antiretroviral drug monitoring (1, 2). So far, however, these methods have not adequately addressed crucial LC/MS/MS configuration and sample preparation parameters required to ensure robustness, cost-effectiveness, and long-term viability.
This application note describes a LC/MS/MS procedure for the simultaneous determination of nine PI and NNRTI antiretroviral drugs that are commonly used in Europe. Using the procedure presented here, these drugs were determined quickly and reproducibly, with minimal sample preparation, operator intervention, and solvent consumption.
Sensitive and selective Multiple Reaction Monitoring (MRM) scan function for linear quantitative analysis with wide dynamic range
Patented LINAC collision cell for multi-component analysis at reduced MRM dwell times maintaining sensitivity and preventing crosstalk
Rugged and reliable triple quadrupole MS system for maximum uptime
Analyst software control of all periph